What is Leerink Partnrs' Forecast for RGLS Q1 Earnings?

Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Regulus Therapeutics in a report issued on Wednesday, April 30th. Leerink Partnrs analyst J. Schwartz expects that the biopharmaceutical company will earn ($0.23) per share for the quarter. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Regulus Therapeutics' current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Regulus Therapeutics' Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2026 earnings at ($1.06) EPS.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.14.

Other equities analysts also recently issued reports about the stock. Leerink Partners reaffirmed a "market perform" rating and set a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Wells Fargo & Company restated an "equal weight" rating and issued a $9.00 target price on shares of Regulus Therapeutics in a research report on Thursday, May 1st. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Friday, March 14th. Jones Trading restated a "hold" rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, Canaccord Genuity Group reaffirmed a "hold" rating and set a $11.00 price objective (down previously from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Regulus Therapeutics presently has an average rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Price Performance

RGLS traded up $0.01 on Monday, reaching $7.86. 243,042 shares of the stock were exchanged, compared to its average volume of 872,470. Regulus Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $8.20. The firm has a market capitalization of $520.67 million, a PE ratio of -7.35 and a beta of 0.49. The company's 50-day moving average price is $2.63 and its 200 day moving average price is $1.83.

Institutional Investors Weigh In On Regulus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. lifted its position in shares of Regulus Therapeutics by 23.1% during the 1st quarter. Federated Hermes Inc. now owns 15,819,863 shares of the biopharmaceutical company's stock worth $27,685,000 after buying an additional 2,967,209 shares during the period. Octagon Capital Advisors LP boosted its position in shares of Regulus Therapeutics by 13.7% during the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock worth $7,661,000 after buying an additional 585,101 shares during the period. Millennium Management LLC grew its position in Regulus Therapeutics by 69.7% in the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after purchasing an additional 900,743 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Regulus Therapeutics by 141.2% during the fourth quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company's stock worth $301,000 after buying an additional 111,485 shares during the last quarter. Finally, Tyche Wealth Partners LLC lifted its holdings in Regulus Therapeutics by 14.6% during the 1st quarter. Tyche Wealth Partners LLC now owns 121,589 shares of the biopharmaceutical company's stock valued at $213,000 after purchasing an additional 15,500 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.